Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Nuo Therapeutics ( (AURX) ) just unveiled an announcement.
On May 14, 2025, Nuo Therapeutics, Inc. and Smith+Nephew, Inc. amended their Distribution Agreement to allow Smith+Nephew to act as a sales agent for Nuo’s Aurix brand products. This interim arrangement, which includes commission-based compensation for Smith+Nephew, will last until December 31, 2025, or until terminated with 30 days’ notice. This amendment enhances the existing agreement where Nuo supplies Smith+Nephew with its private label Aurix products under specific terms for five years.
More about Nuo Therapeutics
Nuo Therapeutics, Inc. operates in the healthcare industry, focusing on the development and commercialization of regenerative therapies. Its primary product, the Aurix brand, is used in wound care and healing, catering to a market that demands innovative medical solutions.
Average Trading Volume: 11,497
Technical Sentiment Signal: Buy
Current Market Cap: $71.17M
See more data about AURX stock on TipRanks’ Stock Analysis page.